www.tevaoctreotide.com
Open in
urlscan Pro
45.60.34.221
Public Scan
Submitted URL: http://tevaoctreotide.com/
Effective URL: https://www.tevaoctreotide.com/
Submission Tags: @phish_report
Submission: On November 20 via api from FI — Scanned from FI
Effective URL: https://www.tevaoctreotide.com/
Submission Tags: @phish_report
Submission: On November 20 via api from FI — Scanned from FI
Form analysis
1 forms found in the DOMGET /en/octreotide/search-result/
<form action="/en/octreotide/search-result/" class="gw-page-search__form" method="get" novalidate="" role="search">
<fieldset class="gw-page-search__set">
<label class="sr-only" for="sg-2d114b">Search</label>
<input id="sg-2d114b" autocomplete="off" class="gw-page-search__input" data-tabindex-collapsed="4" placeholder="type your search" aria-label="type your search" required="" type="search" value="">
<div class="gw-page-search__btn">
<button type="submit" data-tabindex-collapsed="4" class="vi-btn vi-btn-search"> Search </button>
</div>
</fieldset>
<div class="gw-page-search__clear">
<div class="gw-page-search__clear-inset">
<div class="gw-page-search__clear-btn">
<button type="reset" class="vi-btn-search vi-btn-search--clear vi-btn"> Clear </button>
</div>
</div>
</div>
</form>
Text Content
We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience Close Skip to main content Search Search Clear Close * Full Prescribing Information Search * About * Savings * How to Administer * FAQs * Teva's Commitment Menu TEVA OFFERS THE FIRST FDA-APPROVED GENERIC VERSION OF SANDOSTATIN®* LAR DEPOT For the treatment of acromegaly, severe diarrhea/flushing episodes associated with metastatic carcinoid tumors, and profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors Learn more Teva offers the first FDA-approved generic version of Sandostatin®* LAR Depot HOW TO ADMINISTER Intended for Healthcare Professionals only. Learn the administration process for Teva's Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use. Watch video How to Administer PAY AS LITTLE AS $10* FOR TEVA'S OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION, FOR GLUTEAL INTRAMUSCULAR USE *Eligibility requirements apply. Download Savings Card Pay as little as $10* for Teva's Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use TEVA KNOWS GENERICS - IT'S WHAT WE DO. Find out how Teva became a leading producer of generics. Read more Teva knows generics - it's what we do. -------------------------------------------------------------------------------- IMPORTANT SAFETY INFORMATION WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION? Treatment with octreotide acetate for injectable suspension may affect gallbladder function, with reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Tell your doctor if you experience signs or symptoms of gallstones or any of their complications. Patients with carcinoid tumors and VIP-secreting tumors should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms. Patients with acromegaly should adhere to their return visit schedule to help assure steady control of GH and IGF-1 levels. WHAT SHOULD I TELL MY DOCTOR BEFORE TAKING OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION? Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. WHAT ARE THE POSSIBLE SIDE EFFECTS OF OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION? In acromegalic patients, the most common side effects of octreotide acetate for injectable suspension include gallstones, diarrhea, abdominal pain, gas, flu-like symptoms, constipation, headache, low red blood cells, injection-site pain, gallstones, high blood pressure, dizziness and fatigue. In carcinoid tumor and VIP-secreting tumor patients, the most common side effects of octreotide acetate for injectable suspension include back pain, fatigue, headache, abdominal pain, nausea, and dizziness. These are not all of the possible side effects of octreotide acetate for injectable suspension. Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. WHAT IS OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION? Octreotide acetate for injectable suspension is a prescription medication used in patients in whom initial treatment with octreotide acetate injection has been shown to be effective and tolerated for: * Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy, is not an option to reduce GH and IGF-1 levels to normal. * Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. * Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors. In patients with carcinoid tumors and VIP-secreting tumors, the effect of octreotide acetate injection and octreotide acetate for injectable suspension on tumor size, rate of growth and development of metastases, has not been determined. Please see the full Prescribing Information. Toggle Instructions IMPORTANT SAFETY INFORMATION WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION? Treatment with octreotide acetate for injectable suspension may affect gallbladder function, with reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Tell your doctor if you experience signs or symptoms of gallstones or any of their complications. Patients with carcinoid tumors and VIP-secreting tumors should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms. Patients with acromegaly should adhere to their return visit schedule to help assure steady control of GH and IGF-1 levels. WHAT SHOULD I TELL MY DOCTOR BEFORE TAKING OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION? Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. WHAT ARE THE POSSIBLE SIDE EFFECTS OF OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION? In acromegalic patients, the most common side effects of octreotide acetate for injectable suspension include gallstones, diarrhea, abdominal pain, gas, flu-like symptoms, constipation, headache, low red blood cells, injection-site pain, gallstones, high blood pressure, dizziness and fatigue. In carcinoid tumor and VIP-secreting tumor patients, the most common side effects of octreotide acetate for injectable suspension include back pain, fatigue, headache, abdominal pain, nausea, and dizziness. These are not all of the possible side effects of octreotide acetate for injectable suspension. Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. WHAT IS OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION? Octreotide acetate for injectable suspension is a prescription medication used in patients in whom initial treatment with octreotide acetate injection has been shown to be effective and tolerated for: * Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy, is not an option to reduce GH and IGF-1 levels to normal. * Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. * Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors. In patients with carcinoid tumors and VIP-secreting tumors, the effect of octreotide acetate injection and octreotide acetate for injectable suspension on tumor size, rate of growth and development of metastases, has not been determined. Please see the full Prescribing Information. * About Teva's Octreotide * Savings * How to Administer [HCP ONLY] * FAQs * Teva's Commitment to Generics * Full Prescribing Information * Legal Notice * Privacy Notice * Accessibility Statement *Sandostatin® is a registered trademark of Novartis AG Corporation. FOLLOW TEVA * Facebook * Linkedin ©2024 Teva Pharmaceuticals USA, Inc. | TG-43749 September 2024 Click here to go back to top YOU ARE ABOUT TO LEAVE THIS SITE Close The website you are about to access may be governed by different regional policies, regulations or advertising codes. Please be sure to read the privacy policy and terms of use of the websites that you visit. Teva Pharmaceuticals is not responsible for the accuracy or compliance with laws of information on any third party websites. Do you wish to proceed? Go to site This site uses cookies to personalize content, save your preferences, provide social media features, enable personalized advertising and track the site's performance as described in our Privacy Notice in the footer of this site. Please review your Cookie Settings to confirm your choices before continuing to browse this site. You can make changes at any time by accessing the Cookie Settings link in the footer of this site, orclicking here. * YOUR PRIVACY * STRICTLY NECESSARY COOKIES * PERFORMANCE COOKIES * TARGETING COOKIES * FUNCTIONAL COOKIES YOUR PRIVACY This site uses cookies to personalize content, save your preferences, provide social media features, enable personalized advertising and track the site's performance as described in our Privacy Notice. Please review your Cookie Settings to confirm your choices before continuing to browse this site. Privacy Policy STRICTLY NECESSARY COOKIES Always Active These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. PERFORMANCE COOKIES Performance Cookies These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore may be non-directly identifiable. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. TARGETING COOKIES Targeting Cookies These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising. FUNCTIONAL COOKIES Functional Cookies These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly. Back Button COOKIE LIST Filter Button Consent Leg.Interest checkbox label label checkbox label label checkbox label label Clear checkbox label label Apply Cancel Confirm My Choices Allow All